Core Viewpoint - Baosai Tu-B (02315) has shown a significant increase in stock price, rising over 6% following the release of its 2025 performance forecast, indicating strong growth potential in revenue and net profit [1] Group 1: Financial Performance - The company forecasts a revenue of approximately 1.369 billion to 1.389 billion yuan for 2025, representing a year-on-year growth of 39.61% to 41.65% [1] - Expected net profit attributable to shareholders is projected to be between 162 million to 182 million yuan, reflecting a substantial year-on-year increase of 384.26% to 443.88% [1] Group 2: Business Drivers - Guolian Minsheng Securities highlights the company's innovative advantages in model animals and preclinical CRO business, as well as the strengths of its antibody platform supported by the "Thousand Mice, Ten Thousand Antibodies" initiative [1] - Since 2025, the company has established external licensing agreements with several leading domestic and international pharmaceutical companies, and multiple pipelines have received IND approvals, which are expected to contribute to milestone payments and further revenue growth [1]
百奥赛图-B午后涨超6% 25年业绩预告亮眼 对外授权打开长期增长天花板